26,246 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Genesee Capital Advisors LLC

Genesee Capital Advisors LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 26,246 shares of the medical research company’s stock, valued at approximately $2,971,000. Edwards Lifesciences makes up about 1.5% of Genesee Capital Advisors LLC’s portfolio, making the stock its 18th biggest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,357,315 shares of the medical research company’s stock worth $2,419,116,000 after acquiring an additional 186,344 shares in the last quarter. Capital International Investors increased its holdings in Edwards Lifesciences by 5.9% in the 2nd quarter. Capital International Investors now owns 20,002,880 shares of the medical research company’s stock worth $2,071,700,000 after acquiring an additional 1,115,719 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 3.2% during the second quarter. Geode Capital Management LLC now owns 10,224,561 shares of the medical research company’s stock worth $1,055,830,000 after buying an additional 312,507 shares in the last quarter. FMR LLC grew its holdings in shares of Edwards Lifesciences by 45.6% during the second quarter. FMR LLC now owns 7,536,198 shares of the medical research company’s stock worth $780,524,000 after buying an additional 2,358,602 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Edwards Lifesciences by 7.3% during the second quarter. Royal Bank of Canada now owns 6,522,965 shares of the medical research company’s stock worth $675,583,000 after buying an additional 445,786 shares in the last quarter. 80.60% of the stock is owned by institutional investors.

NYSE EW opened at $114.49 on Thursday. The firm’s 50-day moving average is $115.34 and its two-hundred day moving average is $109.68. Edwards Lifesciences Co. has a 12 month low of $78.44 and a 12 month high of $123.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.64 and a quick ratio of 2.87. The stock has a market capitalization of $71.48 billion, a P/E ratio of 48.72, a PEG ratio of 3.69 and a beta of 1.01.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, October 27th. The medical research company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.01. Edwards Lifesciences had a net margin of 29.00% and a return on equity of 28.13%. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the prior year, the company posted $0.51 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.8% compared to the same quarter last year. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.27 EPS for the current year.

In other news, Director Nicholas J. Valeriani bought 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 24th. The shares were purchased at an average cost of $112.23 per share, for a total transaction of $168,345.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 9,741 shares of the company’s stock in a transaction that occurred on Monday, October 18th. The stock was sold at an average price of $110.41, for a total transaction of $1,075,503.81. The disclosure for this sale can be found here. Insiders have sold 146,351 shares of company stock worth $16,970,864 over the last quarter. Insiders own 1.35% of the company’s stock.

A number of equities research analysts have recently issued reports on EW shares. Jefferies Financial Group upped their target price on shares of Edwards Lifesciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, October 29th. Credit Suisse Group upped their target price on shares of Edwards Lifesciences from $126.00 to $130.00 and gave the stock an “outperform” rating in a report on Thursday, October 28th. Oppenheimer upped their target price on shares of Edwards Lifesciences from $97.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $103.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, July 30th. Finally, UBS Group boosted their price target on shares of Edwards Lifesciences from $98.00 to $115.00 and gave the company a “neutral” rating in a research report on Friday, July 30th. Nine investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $117.84.

Edwards Lifesciences Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Featured Story: What is meant by a buy rating?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.